Levosimendan Kalceks (Levosimendan)

• Levosimendan is used in the cardiovascular therapeutic area to improve cardiac performance in severe heart failure states.
• Acute decompensated heart failure: enhances cardiac output and reduces pulmonary congestion in patients with sudden worsening of chronic heart failure.
• Cardiogenic shock: provides inotropic support and vasodilation to stabilize hemodynamics in patients with profound circulatory failure.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous vasodilation that reduces cardiac preload and afterload, improving overall cardiac efficiency.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

• Hypotension: drop in blood pressure, especially during initial infusion.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain due to reduced coronary perfusion.
• Severe hypotension: profound blood pressure fall requiring intervention.
• Anaphylaxis: rare allergic reaction with systemic manifestations.

• Levosimendan requires careful patient assessment and monitoring before and during administration.
• Cardiovascular monitoring: continuously observe blood pressure and heart rate throughout infusion.
• Renal impairment: use with caution in patients with severe renal dysfunction; dose adjustment may be needed.
• Hepatic impairment: consider reduced clearance in liver disease and monitor liver function tests.
• Electrolyte disturbances: correct hypokalemia or other electrolyte imbalances prior to therapy.
• Drug interactions: avoid concurrent use with other potent vasodilators.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid)

• Sodium nitroprusside: additive hypotensive effect may cause severe blood pressure drop.
• Phosphodiesterase inhibitors: combined use can precipitate profound hypotension.
• Beta‑blockers: may blunt the inotropic response of levosimendan.

Moderate Interactions (Monitor Closely)

• Diuretics: increase risk of electrolyte imbalance and dehydration.
• ACE inhibitors: may enhance hypotensive response, requiring dose titration.